BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/26/2019 7:59:48 AM | Browse: 828 | Download: 1868
 |
Received |
|
2019-09-04 20:40 |
|
Peer-Review Started |
|
2019-09-04 20:40 |
|
To Make the First Decision |
|
2019-10-15 00:21 |
|
Return for Revision |
|
2019-10-15 01:51 |
|
Revised |
|
2019-10-28 19:31 |
|
Second Decision |
|
2019-11-22 07:19 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-11-26 01:14 |
|
Articles in Press |
|
2019-11-26 01:14 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-12-06 08:12 |
|
Publish the Manuscript Online |
|
2019-12-26 07:59 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019 Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Observational Study |
| Article Title |
Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Katherine Kutney, Shannon B Donnola, Chris A Flask, Rose Gubitosi-Klug, MaryAnn O'Riodan, Kimberly McBennett, Thomas J Sferra and Beth Kaminski |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| UH Fellowship Research Award Program |
|
|
| Corresponding Author |
Katherine Kutney, MD, Assistant Professor, Department of Pediatric Endocrinology, University Hospitals Cleveland Medical Center, 11100 Euclid Ave., Suite 737, Cleveland, OH 44106, United States. katherine.kutney@uhhospitals.org |
| Key Words |
Cystic fibrosis; Liver disease; Non-alcoholic fatty liver disease; Cystic fibrosis transmembrane conductance regulator; Lumacaftor/ivacaftor; Cystic fibrosis transmembrane conductance regulator modulator |
| Core Tip |
Hepatic steatosis is a common manifestation of liver disease in cystic fibrosis (CF). It remains unknown whether hepatic steatosis contributes to the development of cirrhosis in patients with CF. Lumacaftor/ivacaftor is a cystic fibrosis transmembrane conductance regulator (CFTR) modulator drug targeting the defective chloride channel that causes CF. In this cross-sectional study, CF patients receiving lumacaftor/ivacaftor had significantly lower magnetic resonance imaging proton density fat fractions than CF patients not receiving the CFTR modulator. CFTR modulator use should be included in future studies of CF liver disease. |
| Publish Date |
2019-12-26 07:59 |
| Citation |
Kutney K, Donnola SB, Flask CA, Gubitosi-Klug R, O’Riordan M, McBennett K, Sferra TJ, Kaminski B. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients. World J Hepatol 2019; 11(12): 761-772 |
| URL |
https://www.wjgnet.com/1948-5182/full/v11/i12/761.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v11.i12.761 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
